Business Context and Reporting Period
This Form 8-K was filed by Xcyte Therapies, Inc. on January 13, 2006. The report details a material definitive agreement involving an amendment to a Stock Purchase Agreement originally dated December 15, 2005, between Xcyte and Cyclacel Group plc.
Key Financial Metrics
This filing is a current report regarding a corporate transaction and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Amendment to Stock Purchase Agreement: Xcyte and Cyclacel entered into an amendment removing a specific condition precedent from the original agreement.
- Removal of Liquidation Approval Condition: The original agreement required Cyclacel shareholders to approve a members voluntary liquidation as a condition to consummate the transaction. The amendment removes this requirement, allowing the parties to proceed without this specific shareholder approval.
Guidance, Outlook, and Risks
Next Steps: Xcyte intends to file a registration statement on Form S-4 containing a proxy statement/prospectus to seek stockholder approval for the share issuance and other matters related to the transaction.
Risks and Uncertainties: The filing includes forward-looking statements subject to several risks, including:
- Failure of Xcyte stockholders to approve the proposed transactions.
- Failure to obtain required regulatory approvals.
- Delays in closing or failure of the transaction to close entirely.
- Failure to make the purchase price payment.
Investor Verification Checklist
- Verify the terms of the Amendment No. 1 filed as Exhibit 2.1 to understand the full scope of changes to the Stock Purchase Agreement.
- Monitor the upcoming Form S-4 filing for the proxy statement/prospectus, which will contain critical details on the share issuance and special interests of directors and officers.
- Confirm the status of stockholder approval required for the transaction to proceed.
- Review Xcyte's periodic filings for additional risk factors not detailed in this specific 8-K.